Eli Lilly (LLY) rated Sell/Avoid: overvaluation, slowing GLP-1 growth, Novo competition, bearish technicals and insider ...
Ladies and gentlemen, thank you for standing by, and I would like to welcome you to Allegro's Q4 2025 Results Conference Call. [Operator Instructions] So without further ado, I will now pass the line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results